Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.

CONCLUSION: At tolerable doses, the combination of sorafenib and capecitabine seems an active and safe palliative treatment for HCC in class A and B-7 patients with cirrhosis. The small sample size does not allow comparison with single-agent sorafenib. PMID: 28687627 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28687627?dopt=Abstract

Source: The Oncologist - July 7, 2017 Category: Cancer & Oncology Authors: Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC Tags: Oncologist Source Type: research